

# UNCLASSIFIED

AD NUMBER
ADB257354
NEW LIMITATION CHANGE
TO Approved for public release, distribution unlimited
FROM Distribution authorized to U.S. Gov't. agencies only; Proprietary information; Jul 1999. Other requests shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, MD, 21702-5012.
AUTHORITY
USAMRMC ltr, 5 Mar 2002

THIS PAGE IS UNCLASSIFIED

AD\_\_\_\_\_

GRANT NUMBER DAMD17-97-1-7176

TITLE: Identification and Characterization of Distinct Apoptotic Pathways in Cancer Cells Activated in Response to Treatment with Different Anti-Cancer Agents

PRINCIPAL INVESTIGATOR: Julia Polyakova

CONTRACTING ORGANIZATION: Cold Spring Harbor Laboratory  
Cold Spring Harbor, New York 11724

REPORT DATE: July 1999

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government agencies only (proprietary information, Jul 99). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

DTIC QUALITY INSPECTED 4

20000829 031

## NOTICE

USING GOVERNMENT DRAWINGS, SPECIFICATIONS, OR OTHER DATA INCLUDED IN THIS DOCUMENT FOR ANY PURPOSE OTHER THAN GOVERNMENT PROCUREMENT DOES NOT IN ANY WAY OBLIGATE THE U.S. GOVERNMENT. THE FACT THAT THE GOVERNMENT FORMULATED OR SUPPLIED THE DRAWINGS, SPECIFICATIONS, OR OTHER DATA DOES NOT LICENSE THE HOLDER OR ANY OTHER PERSON OR CORPORATION; OR CONVEY ANY RIGHTS OR PERMISSION TO MANUFACTURE, USE, OR SELL ANY PATENTED INVENTION THAT MAY RELATE TO THEM.

### LIMITED RIGHTS LEGEND

Award Number: DAMD17-97-1-7176

Organization: Cold Spring Harbor Laboratory

Those portions of the technical data contained in this report marked as limited rights data shall not, without the written permission of the above contractor, be (a) released or disclosed outside the government, (b) used by the Government for manufacture or, in the case of computer software documentation, for preparing the same or similar computer software, or (c) used by a party other than the Government, except that the Government may release or disclose technical data to persons outside the Government, or permit the use of technical data by such persons, if (i) such release, disclosure, or use is necessary for emergency repair or overhaul or (ii) is a release or disclosure of technical data (other than detailed manufacturing or process data) to, or use of such data by, a foreign government that is in the interest of the Government and is required for evaluational or informational purposes, provided in either case that such release, disclosure or use is made subject to a prohibition that the person to whom the data is released or disclosed may not further use, release or disclose such data, and the contractor or subcontractor or subcontractor asserting the restriction is notified of such release, disclosure or use. This legend, together with the indications of the portions of this data which are subject to such limitations, shall be included on any reproduction hereof which includes any part of the portions subject to such limitations.

THIS TECHNICAL REPORT HAS BEEN REVIEWED AND IS APPROVED FOR PUBLICATION.

  
\_\_\_\_\_

\_\_\_\_\_

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.				
1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE July 1999	3. REPORT TYPE AND DATES COVERED Annual (1 Jul 98 - 30 Jun 99)	
4. TITLE AND SUBTITLE Identification and Characterization of Distinct Apoptotic Pathways in Cancer Cells Activated in Response to Treatment with Different Anti-Cancer Agents			5. FUNDING NUMBERS DAMD17-97-1-7176	
6. AUTHOR(S) Polyakova, Julia				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Cold Spring Harbor Laboratory Cold Spring Harbor, New York 11724			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Distribution authorized to U.S. Government agencies only (proprietary information, Jul 99). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 words) The adenovirus E1A oncoprotein sensitizes primary cells to undergo apoptosis following treatment with anticancer agents through a mechanism involving inactivation of the retinoblastoma (Rb) protein and stabilization of p53 tumor suppressor. Anticancer agents ultimately induce apoptosis by activating caspases, a family of cystein proteases that are essential components of the cell death machinery. Caspases are expressed as latent pro-enzymes and processed to active enzymes during apoptotic cell death. To further understand the mechanism whereby E1A promotes chemosensitivity, we examined pro-caspase levels in primary fibroblasts expressing E1A. Introduction of E1A greatly increased the levels of pro-caspases 2, 3, 7 and 8 through a post-transcriptional mechanism. The Rb binding domain of E1A is essential for pro-caspase induction, indicating that inactivation of Rb contributes to this effect. In contrast, the p53 and p19 <sup>ARF</sup> tumor suppressors are dispensable for caspase induction, since E1A induces pro-caspase levels in p53 <sup>-/-</sup> and ARF <sup>-/-</sup> MEFs. Nevertheless, the ability of E1A to induce pro-caspases and p53 may synergize to promote apoptosis. These studies provide a direct connection between a pro-apoptotic oncogene (E1A) and the cell death machinery. Caspase induction by E1A may contribute to its ability to promote chemosensitivity.				
14. SUBJECT TERMS Breast Cancer apoptosis, caspases, anticancer drugs, E1A oncogene			15. NUMBER OF PAGES 23	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Limited	

## FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

\_\_\_\_ Where copyrighted material is quoted, permission has been obtained to use such material.

\_\_\_\_ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

\_\_\_\_ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

✓ In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

\_\_\_\_ For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

JP ✓ In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

JP ✓ In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

\_\_\_\_ In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

  
\_\_\_\_  
PI - Signature

7/25/99  
\_\_\_\_  
Date

## TABLES OF CONTENTS

FRONT COVER

REPORT DOCUMENTATION PAGE

FOREWORD

INTRODUCTION

BODY

**Aim 1.** Identification and characterization of distinct apoptotic pathways in E1A/ras-transformed MEFs.

**Aim 2.** Identification of caspases activated during distinct apoptotic programs in ER/MEFs.

- Identification of caspases expressed in wild-type E1A/ras/MEFs.

**Aim 3.** Establishing the role of Caspase-2 in distinct forms of apoptosis in oncogenically transformed mouse embryo fibroblasts.

**Aim 4.** Determination of the mechanism by which the E1A oncogene induces the pro-caspase levels.

- Determination of E1A protein regions responsible for caspase induction.
- Establishing the role of Rb in regulation of the pro-caspase levels.
- Determination of the level at which Rb-dependent caspase suppression occurs.
- Identification of Rb partners acting in Rb-dependent pathway of suppression of the pro-caspase levels.

APPENDICES

## INTRODUCTION

Apoptosis is a programmed form of cell death that plays an important role in malignancy by shifting the balance from tumor proliferation to its regression. Anticancer drugs act by activating apoptosis in tumor cells. Mutations in apoptotic pathways can lead to anticancer drug resistance and therefore can promote tumor progression. Our lab is working to elucidate the molecular mechanisms of apoptosis in oncogenically-transformed primary Mouse Embryo Fibroblasts (MEFs). We have chosen this model system because of the fact that it lacks mutations and alterations that are common to immortal cell lines; of the ability to use genetic approach to study apoptosis (availability of knock-out mouse lines); of the ease of gene manipulations (retroviral mediated gene transfer technique) in MEFs. The adenovirus E1A oncoprotein sensitizes primary cells to undergo apoptosis following treatment with anticancer agents. It was shown that E1A induced sensitivity in MEFs is similar to chemosensitivity of spontaneous tumors. We expect that further insight into mechanisms of programmed cell death in oncogenically-transformed MEFs will provide a fuller understanding of the role of apoptosis in real tumor progression such as breast cancer and will lead to the developing new strategies for anti-cancer therapy.

I am interested in determining the role of caspases in apoptosis in MEFs. Caspases are a family of cystein proteases that are expressed in latent pro-enzyme forms. Caspases are essential components of apoptotic machinery, and activation of pro-caspases is an obligatory step in the induction and execution of apoptosis triggered by many anticancer drugs. The goal of my thesis project is to identify caspases that are involved in programmed cell death in primary MEFs, to reveal caspases activated during distinct apoptotic programs, to determine the effect of E1A expression on caspases in the cells and finally to establish the role of one particular caspase in distinct forms of apoptosis in oncogenically-transformed MEFs.

## BODY

**Aim 1.** Identification and characterization of distinct apoptotic pathways in E1A/ras-transformed MEFs.

Aim 1 was completed during previous year.

**Aim 2.** Identification of caspases activated during distinct apoptotic programs in ER/MEFs.

Identification of caspases expressed in wild-type E1A/ras/MEFs.

Nine members of mouse caspase family have been identified. I have established that Caspases-2,3,6,7,8 are expressed in primary MEFs at the RNA

level (fig. 1). Caspases-2,3,7,8 and 11 can also be detected at the protein level (fig. 2). Introduction of E1A oncogene greatly increased protein level of the unprocessed forms of the tested caspases. Moreover, caspase induction was p53 independent. I detected little, if any, induction of caspases at mRNA levels. That argues that this process might occur at the translational or post-translational levels. For example, E1A could somehow alter protein stability of pro-caspases.

E1A oncoprotein is known to sensitize cells to undergo apoptosis following treatment with anticancer agents through a mechanism involving inactivation of retinoblastoma (Rb) protein and stabilization of p53 tumor suppressor. The downstream events of this mechanism remain to be discovered. Anticancer agents ultimately induce apoptosis by activating caspases. Caspases are expressed as latent pro-enzymes and processed to active enzymes during apoptotic cell death. It is feasible that the high levels of pro-caspases that are available for activation by apoptotic agents could predispose cells to apoptosis. Caspase induction by E1A may be a part of the mechanism by which E1A promote chemosensitivity.

Since E1A promotes apoptosis and causes dramatic induction of pro-caspases I have focused my research on mechanism of pro-caspase induction by E1A (see Aim 4).

#### Generation of monoclonal antibodies against mouse caspases expressed in E1A/ras/MEFs.

This task was completed during previous year.

#### Establishing the pattern of caspase activation in wild-type E1A/ras/MEFs.

This task was completed during previous year.

**Aim 3.** Establishing the role of Caspase-2 in distinct forms of apoptosis in oncogenically transformed mouse embryo fibroblasts.

Aim 3 was completed during previous year.

**Aim 4.** Determination of the mechanism by which the E1A oncogene induces the pro-caspase levels.

My results from Northern blot analysis of caspase expression clearly showed that pro-caspase induction by E1A occurred on post-transcriptional level (fig. 1). Moreover this induction was independent on p53 function since E1A oncogene still induced pro-caspases in p53<sup>-/-</sup> cells (fig. 2).

#### Determination of E1A protein regions responsible for caspase induction.

I used several E1A deletion mutants that are known to bind certain cellular factors (fig. 3). I introduced these mutants to wild type MEFs and by Western blot analysis with anti-caspase antibodies I have established that the CR2 region



of E1A and possibly the N-terminal region are responsible for caspase upregulation (fig. 4). CR2 region of E1A is known to bind members of Rb family of pocket proteins. For all the pro-caspases that were tested deltaCR2 mutant of E1A was unable to induce pro-caspase levels. To prove that observed effect was not species-specific, I have shown that CR2 region of E1A was responsible for caspase induction in human fibroblasts (IMR90) (fig. 4). The N-terminal region of E1A is known to bind p300 protein. I have determined that this region was important for Caspase-7 induction both in mouse and human fibroblasts. (fig. 4)

#### Establishing the role of Rb in regulation of the pro-caspase levels.

Since CR2 region of E1A can to bind such pocket proteins as Rb, p107, p130 and Rb is required for chemosensitization of MEFs, I decided to determine whether one of the functions of Rb in the normal cell is to block pro-caspase induction.

I compared pro-caspase levels between wild type MEFs and Rb<sup>-/-</sup> MEFs. Expression of caspases in Rb<sup>-/-</sup> cells was increased compared to wild type MEFs (Fig. 5). For several caspases these levels were comparable to levels that were observed upon introduction of wild type E1A. For others, these levels were lower (data not shown). Nevertheless, these results clearly showed that Rb blocked pro-caspase expression in primary cells. Also these results argue that Rb may synergize with other cellular protein(s) possibly p300 that is known to bind the N-terminal region of E1A to repress pro-caspases.

To prove that it was Rb that was responsible for pro-caspase induction, I introduced all the above E1A mutants into Rb<sup>-/-</sup> MEFs with the expectation that in this background the deltaCR2 E1A mutant will not have any defect in caspase upregulation. For all tested caspases the results were like expected (fig. 6).

Next, I reintroduced Rb back into Rb<sup>-/-</sup> cells and proved that pro-caspase levels have diminished. I accomplished this by utilizing temperature-sensitive human Rb mutants (Tiemann, F. et al). Osteocarcinoma cell lines (ts1 and ts2) that stably express tsRb were used in this experiment. I grew these cells at permissive and non-permissive temperatures. Rb protein was not expressed at non-permissive temperature. I monitored the suppression of pro-caspase induction by Western blot analysis with anti-caspase antibodies (fig. 7). I used two osteocarcinoma cell lines U2OS (Rb positive) and SAOS 2 (Rb negative) as controls. All these data together clearly demonstrated that induction of pro-caspases in the cells by E1A occurred mostly by inactivation of Rb protein and that one of the function of Rb was to block pro-caspase upregulation.

To determine whether pro-caspase induction alone could lead to chemosensitivity I treated wt MEFs, Rb<sup>-/-</sup>MEFs, wt E1A, Rb<sup>-/-</sup> E1A with adriamycin, an anticancer agent. Apoptosis was scored by Trypan blue exclusion and DAPI (fig. 8). I have shown that increased levels of pro-caspases could stimulate chemosensitivity (compare wt MEFs and Rb<sup>-/-</sup>MEFs), but alone were not sufficient for complete chemosensitivity (compare Rb<sup>-/-</sup>MEFs and wt E1A).

Determination of the level at which Rb-dependent pro-caspase suppression occurs.

A. Transcription.

From the Northern blot analysis I have already established that mRNA levels of the caspases were practically the same in primary and E1A infected cells. This observation argues that Rb-dependent regulation occurs at the protein level.

B. Stability.

It is known that E1A stabilizes p53 protein levels, in part by inactivating Rb. Therefore, I predict that E1A would also stabilize pro-caspases. To determine this I plan to perform the following series of experiments.

- I will measure caspase turnover in primary MEFs and E1A infected MEFs by a pulse chase experiment.
- Next, I plan to use proteasome specific inhibitors on wt primary MEFs to see the possible induction of caspase levels (Dick L. et al).
- I will take advantage of ts cell line defective in the ubiquitin pathway to look for induction of caspase levels at non-permissive temperature (Chowdary D. et al).

C. Translation.

In the case when I would not be able to detect pro-caspase regulation on protein stability level I plan to look for the possibility of regulation on the level of translation.

- I will use translation efficiency assay (polysome gradient) to measure the levels of caspases translation (Mullner E.W. et al, Fagan R.J. et al).

Identification of the Rb partners acting in Rb-dependent pathway of suppression of the pro-caspase levels.

Many cellular proteins have been identified to interact with Rb. Among them are E2F1, Mdm2, Cyclin D. Other proteins were shown to modulate Rb activity – p16, p21. P19 was recently shown to promote Mdm2 degradation and stabilization of p53 in the cells. I took advantage of available knock-out mouse strains to determine which of those molecules participate in stabilization (destabilization) of pro-caspases.

I compared the ability of E1A to induce pro-caspase levels in wild type and E2F1<sup>-/-</sup>; p19<sup>-/-</sup>, p16<sup>-/-</sup> MEFs (fig. 9). My data showed that Rb-dependent pro-caspase suppression did not require E2F1, p16 and p19.

Overexpression of E2F1 alone was sufficient to induce apoptosis in E1A/MEFs. I overexpressed E2F1 in wt MEFs and in p53<sup>-/-</sup>MEFs to determine the ability of this protein to induce pro-caspase levels (fig. 10). Since E2F1 induced massive apoptosis in wt MEFs, I looked for the effect of E2F1

overexpression in p53<sup>-/-</sup>-MEFs (I already have established that pro-caspase induction was p53 independent). My results argue that overexpression of E2F1 transcription factor is sufficient to induce pro-caspase levels. Since my previous results showed precisely that it was not E2F1 itself that was responsible for pro-caspase induction other member of E2F family possibly could do this job.

Mdm2 is playing an important role in regulation of p53 levels in the cells. It was shown that Mdm2 can possibly bind Rb. Mdm2 is one of the molecules that are cleaved during early stages of apoptosis by caspases. To determine the role of Mdm2 in pro-caspase regulation I overexpressed Mdm2 in wt E1A MEFs and in p53<sup>-/-</sup>-MEFs to look for possible suppression of caspase induction and in wt MEFs to look for pro-caspase induction (fig. 11). My data showed none of these effects.

The results obtained in Aim2 and Aim4 provided the evidence that links apoptotic cell machinery with ability of E1A to sensitize cells to apoptosis. The molecular mechanisms of E1A promoted chemosensitivity remains poorly understood. Such events as inactivation of the retinoblastoma protein, release of E2F's transcription factors and stabilization of p53 through p19 were shown to be important but not sufficient for the full chemosensitivity. My work provided an evidence for another possible mechanism of E1A-induced E2F's mediated chemosensitivity that can be accomplished by the synergy of pro-caspase induction with p53 stabilization (fig. 12).

## APPENDICES

### Key research accomplishments

1. E1A induces pro-caspases on the protein level
2. This induction is p53-independent
3. This induction occurs mostly through the inactivation of Rb protein
4. Rb blocks pro-caspase induction
5. Increased levels of pro-caspases can stimulate chemosensitivity
6. Increased levels of pro-caspases alone are not sufficient for complete chemosensitivity
7. Rb-dependent pro-caspase suppression does not require E2F1, p16 and p19
8. Overexpression of Mdm2 and Bcl2 oncogenes does not alter pro-caspase levels
9. Overexpression of E2F1 transcription factor induces pro-caspases

### References

Tiermann, F. and Hinds, P.W. (1998) Induction of DNA synthesis and apoptosis by regulated inactivation of a temperature-sensitive retinoblastoma protein. EMBO 17, 1040-1052.


Dick, L.R., Cruikshank, A.A., Grenier, L., Melandri, F.D., Nunes, S.L., and Stein, R.L. (1996). Mechanistic studies on the inactivation of the proteasome by lactacystin: a central role for clasto-lactacystin beta-lactone. J Biol Chem 271, 7273-7276.

Chowdary, D.R., Dermody, J.J., Jha, K.K., and Ozer, H.L. (1994). Accumulation of p53 in a mutant cell line defective in the ubiquitin pathway. Mol Cell Biol 14, 1997-2003.


Mullner, E.W., Neupert, B., and Kuhn, L.C. (1989) A specific mRNA binding factor regulates the iron-dependent stability of cytoplasmic transferrin receptor mRNA. Cell 58, 373-382.

Fagan, R.J., Lazaris-Karatzas, A., Sonenberg, N., and Rozen, R. Translational control of ornithine aminotransferase. J Biol Chem 266, 16518-16523.

# Northern blot analysis of caspase expression in primary MEFs vs. E1A infected MEFs



# Western blot analysis of caspase expression in untreated MEFs



# Structure of E1A mutants




Fig. 3

## CR2 region of E1A is required for pro-caspase induction in wild-type primary cells







Fig. 5

## Rb blocks caspase induction



# Deletion of CR2 region in E1A does not prevent pro-caspase induction in Rb-/- MEFs




Fig. 6

# Inactivation of a temperature-sensitive Rb protein induces pro-Caspase 7 levels in osteosarcoma cell line SAOS 2




Fig. 7

# Induction of pro-caspases is not sufficient for chemosensitivity induced by E1A




Fig. 8

# Rb-dependent pro-Caspase 7 induction does not require E2F1 transcription factor, p16 and p19




Fig. 9

# Overexpression of E2F1 in primary MEFs induces pro-Caspase 7 levels




Fig. 10

# Overexpression of Mdm2 does not alter pro-caspase levels




Fig. 11

# Model of E1A Induced Chemosensitivity in Primary MEF's




Fig. 12





7

**DEPARTMENT OF THE ARMY**  
US ARMY MEDICAL RESEARCH AND MATERIEL COMMAND  
504 SCOTT STREET  
FORT DETRICK, MARYLAND 21702-5012

REPLY TO  
ATTENTION OF:

MCMR-RMI-S (70-1y)

5 Mar 02

MEMORANDUM FOR Administrator, Defense Technical Information  
Center (DTIC-OCA), 8725 John J. Kingman Road, Fort Belvoir,  
VA 22060-6218

SUBJECT: Request Change in Distribution Statements

1. The U.S. Army Medical Research and Materiel Command has reexamined the need for the limitation assigned to technical reports written for grants. Request the limited distribution statements for Accession Documents listed at enclosure be changed to "Approved for public release; distribution unlimited." These reports should be released to the National Technical Information Service.

2. Point of contact for this request is Ms. Judy Pawlus at DSN 343-7322 or by e-mail at judy.pawlus@det.amedd.army.mil.

FOR THE COMMANDER:

Encl

PHYLLIS M. RINEHART  
Deputy Chief of Staff for  
Information Management

DISTRIBUTION TO BE CHANGED TO UNLIMITED,  
APPROVED FOR PUBLIC RELEASE

ACCESSION DOCUMENT NUMBERS

ADB267943	ADB267947
ADB257308	ADB268439
ADB233733	ADB242952
ADB263445	ADB248375
ADB258807	ADB240661
ADB257354	ADB271166
ADB240907	ADB258706
ADB270764	ADB244250
ADB241926	ADB258773
ADB246527	ADB254490
ADB268422	ADB268189
ADB252915	ADB270793
ADB258877	ADB266144
ADB268117	ADB236672
ADB267884	ADB259031
ADB254260	ADB270765
ADB268296	ADB270785
ADB258930	ADB268113
ADB271098	ADB270791